All In MedTech

Device Trial Radar · NCT02202434

Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement

REPRISE III: Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Randomized Clinical Evaluation

Last checked: Nov 20, 2026Latest source record: Dec 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 1,425 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,425

Actual

Start

Sep 22, 2014

Primary completion

Mar 8, 2017

Study completion May 21, 2021

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Jul 29, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety and effectiveness of the Lotus™ Valve System and LOTUS Edge™ Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with calcific, severe native aortic stenosis who are considered at extreme or high risk for surgical valve replacement.

Conditions

  • Aortic Stenosis

Interventions

  • Lotus Valve SystemDevice

    Procedure: Transcatheter aortic valve replacement (TAVR)

  • CoreValve/Evolut R Transcatheter Aortic Valve Replacement SystemDevice

    Procedure: Transcatheter aortic valve replacement (TAVR)

  • LOTUS Edge Valve SystemDevice

    Procedure: Transcatheter aortic valve replacement (TAVR)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Events Included in the Primary Safety EndpointTime frame: 30 days following procedure
  2. Percentage of Participants With Events Included in the Primary Effectiveness EndpointTime frame: 1 year following procedure

Locations

58 sites in 6 countries. Site status is shown where the registry gives one.

  • Banner Good Samaritan

    Phoenix, Arizona

  • Scottsdale Healthcare - Shea

    Scottsdale, Arizona

  • Scripps Clinic

    La Jolla, California

55 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.